Referral Rate, Profile and Degree of Control of Patients with Familial Hypercholesterolemia: Data from a Single Lipid Unit from a Mediterranean Area

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2023 May 11

PMID 37170237

Authors

Enric Serra-Planas

Affiliations

Soon will be listed here.

Abstract

Background: The challenging rigorous management of hypercholesterolemia promotes referral to specialized units. This study explored the need, based on referral rate and cardiovascular (CV) risk factor control in patients evaluated for familial hypercholesterolemia (FH), for a lipid unit (LU).

Methods: Over a four-year period, 340 referrals to our unit were analyzed to establish the lipid disorder referral rate. Moreover, 118 patients referred for potential FH during the period 2010-2018 (52.4 ± 13.9 years, 47.5% male, Caucasian, 26.3% obese, 33.1% smokers and 51.7% with some glycaemic alteration) were investigated. The Dutch Lipid Clinic Network (DLCN) score, type and dose of lipid-lowering drugs, lipid profile including lipoprotein (a) (Lp(a)) and the presence of plaques with carotid ultrasound (CU) were recorded.

Results: Lipids represented 6.2% of referrals (38 patient-years) requiring a 2-3 h weekly monographic outpatient consultation. The potential FH sample displayed a DLCN score ≥ 6 in 78% and modifiable CV risk factors in 51%. Only 22% achieved tight disease control despite intensive treatment. The statin-ezetimibe combination treatment group achieved better goals (73.0% vs. 45.5%, P = 0.003), and the rosuvastatin group had a higher proportion of prediabetes (60.9% vs. 39.1%, P = 0.037). Neither CU plaque presence nor Lp(a) > 50 mg/dL was linked with established CV disease patients, but higher Lp(a) concentrations were detected between them (102.5 (26.3-145.8) vs. 25.0 (13.0-52.0) mg/dL, P = 0.012).

Conclusions: The referral rate, degree of control, and proportion of modifiable CV risk factors in FH patients demonstrate the need for LU in our area as well as optimize control and treatment.

References

Hu P, Dharmayat K, Stevens C, Sharabiani M, Jones R, Watts G . Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141(22):1742-1759. DOI: 10.1161/CIRCULATIONAHA.119.044795. View

Froylan D M, Esteban J, Carlos P, Aida X M, Ma Rocio M, Horacio O . Prevalence of poor lipid control in patients with premature coronary artery disease. Nutr Metab Cardiovasc Dis. 2020; 30(10):1697-1705. DOI: 10.1016/j.numecd.2020.04.030. View

Paquette M, Bernard S, Cariou B, Hegele R, Genest J, Trinder M . Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021; 41(10):2632-2640. DOI: 10.1161/ATVBAHA.121.316106. View

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

Cuchel M, Bruckert E, Ginsberg H, Raal F, Santos R, Hegele R . Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014; 35(32):2146-57. PMC: 4139706. DOI: 10.1093/eurheartj/ehu274. View

Valdes S, Garcia-Torres F, Maldonado-Araque C, Goday A, Calle-Pascual A, Soriguer F . Prevalence of obesity, diabetes and other cardiovascular risk factors in Andalusia (southern Spain). Comparison with national prevalence data. The Di@bet.es study. Rev Esp Cardiol (Engl Ed). 2014; 67(6):442-8. DOI: 10.1016/j.rec.2013.09.029. View

Jellinger P, Handelsman Y, Rosenblit P, Bloomgarden Z, Fonseca V, Garber A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017; 23(Suppl 2):1-87. DOI: 10.4158/EP171764.APPGL. View

Ramos R, Masana L, Comas-Cufi M, Garcia-Gil M, Marti-Lluch R, Ponjoan A . Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. Atherosclerosis. 2019; 292:42-51. DOI: 10.1016/j.atherosclerosis.2019.10.016. View

Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J . Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol. 2008; 102(9):1187-93, 1193.e1. DOI: 10.1016/j.amjcard.2008.06.056. View

10.

Climent E, Marco-Benedi V, Benaiges D, Pinto X, Suarez-Tembra M, Plana N . Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis. 2021; 31(5):1594-1603. DOI: 10.1016/j.numecd.2021.01.014. View

11.

Scicali R, Di Pino A, Platania R, Purrazzo G, Ferrara V, Giannone A . Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile. Nutr Metab Cardiovasc Dis. 2017; 28(1):35-43. DOI: 10.1016/j.numecd.2017.07.003. View

12.

. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S17-S38. DOI: 10.2337/dc22-S002. View

13.

Perez-Calahorra S, Laclaustra M, Marco-Benedi V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N . Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis. 2019; 284:245-252. DOI: 10.1016/j.atherosclerosis.2019.02.003. View

14.

Sanchez-Chaparro M, Perez-Martinez P, Ibarretxe D, Suarez-Tembra M, Valdivielso P . Criteria for referring patients to Spanish Atherosclerosis Society lipid units. Clin Investig Arterioscler. 2018; 31(1):26-30. DOI: 10.1016/j.arteri.2018.04.005. View

15.

de Isla L, Alonso R, Mata N, Fernandez-Perez C, Muniz O, Diaz-Diaz J . Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017; 135(22):2133-2144. DOI: 10.1161/CIRCULATIONAHA.116.024541. View

16.

Galve E, Cordero A, Cequier A, Ruiz E, Gonzalez-Juanatey J . Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. Rev Esp Cardiol (Engl Ed). 2016; 69(10):931-938. DOI: 10.1016/j.rec.2016.02.012. View

17.

Ruscica M, Sirtori C, Corsini A, Watts G, Sahebkar A . Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacol Res. 2021; 173:105812. DOI: 10.1016/j.phrs.2021.105812. View

18.

Vallejo-Vaz A, Ray K . Epidemiology of familial hypercholesterolaemia: Community and clinical. Atherosclerosis. 2018; 277:289-297. DOI: 10.1016/j.atherosclerosis.2018.06.855. View

19.

Pedro-Botet J, Climent E, Giralt Martinez E, Flores-Le Roux J . [Map of resources and healthcare needs for patients with dyslipidaemia in Spain: The MADI study]. Clin Investig Arterioscler. 2016; 28(6):257-264. DOI: 10.1016/j.arteri.2016.06.005. View

20.

Trias F, Pinto X, Corbella E, Suarez-Tembra M, Ruiz-Garcia A, Diaz-Diaz J . Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc). 2021; 158(11):531-539. DOI: 10.1016/j.medcli.2021.06.018. View